Grace Therapeutics

(NASDAQ) ACST

Current PriceN/A

Market CapN/A

Since IPO (2011)-100%

5 YearN/A

1 Year-14%

1 Month-52%

Grace Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$4.83M

Net Income (TTM)

$8.57M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

ACST News

Why Shares of Acasti Pharma Slumped Tuesday

James HalleyAug 31, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Grace Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Prashant Kohli, MBA

Website

www.gracetx.com

Headquarters

Laval, QC H7E 2B5, CA

ACST Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-11%

Return on Capital

-18%

Return on Assets

-10%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$0.00

EBITDA

$0.00

Operating Cash Flow

$14.90M

Capital Expenditure

$0.00

Free Cash Flow

$14.90M

Cash & ST Invst.

$22.13M

Total Debt

$0.00

Grace Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$2.31M

+51.4%

EBITDA

$0.00

N/A

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Net Cash

$18.67M

+68.9%

Accounts Receivable

$20.00K

-93.4%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-9.99%

N/A

Return on Invested Capital

-18.10%

N/A

Free Cash Flow

$2.22M

+64.0%

Operating Cash Flow

$2.22M

+64.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IRDOpus Genetics, Inc.

IRDOpus Genetics, Inc.$5.14+0.59%

IGXTIntelGenx Technologies Corp.

IGXTIntelGenx Technologies Corp.$0.17+0.00%

LUMOLumos Pharma, Inc.

LUMOLumos Pharma, Inc.$4.34+0.00%

LIANYLianBio

LIANYLianBio$0.12+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

RIVNRivian Automotive

RIVNRivian Automotive$15.02-0.08%

FFord Motor Company

FFord Motor Company$11.88-0.02%

Questions About ACST

What is the current price of Grace Therapeutics?

Grace Therapeutics is trading at N/A per share.

What is the 52-week range for Grace Therapeutics?

Over the past 52 weeks, Grace Therapeutics has traded between N/A and N/A.

How much debt does Grace Therapeutics have?

As of the most recent reporting period, Grace Therapeutics reported total debt of N/A.

How much cash does Grace Therapeutics have on hand?

Grace Therapeutics reported $18.67M in cash and cash equivalents in its most recent financial results.

What is Grace Therapeutics’s dividend yield?

Grace Therapeutics does not currently have a dividend yield.

Grace Therapeutics

Grace Therapeutics Financials at a Glance

ACST News

Why Shares of Acasti Pharma Slumped Tuesday

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Grace Therapeutics

ACST Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Grace Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ACST

What is the current price of Grace Therapeutics?

What is the 52-week range for Grace Therapeutics?

How much debt does Grace Therapeutics have?

How much cash does Grace Therapeutics have on hand?

What is Grace Therapeutics’s dividend yield?

Premium Investing Services